Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPERO extension study of tozorakimab in COPD with prior exacerbations
CTR20232953Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tozorakimab with Placebo (2 arms). Started Aug 2023; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20232953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232953.